<DOC>
	<DOCNO>NCT01914718</DOCNO>
	<brief_summary>The aim study evaluate efficacy toxicity dose-adjusted EPOCH-R patient MYC positive diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>Dose-adjusted EPOCH-R MYC Positive DLBCL</brief_title>
	<detailed_description>The prognosis MYC positive diffuse large B-cell lymphoma ( DLBCL ) poor even treat R-CHOP regimen . Recently , dose-adjusted EPOCH-R show effective patient DLBCL relapsed/refractory Burkitt lymphoma . The aim study evaluate efficacy toxicity dose-adjusted EPOCH-R patient MYC positive diffuse large B-cell lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Previously untreated MYC positive diffuse large Bcell lymphoma Age range 1870 year old Eastern Cooperative Oncology Group performance status 02 Life expectancy 3 month Adequate organ function Primary secondary central nervous system involvement Previous serious cardiac disease History malignancies except cure basal cell carcinoma skin carcinoma insitu uterine cervix Pregnant lactate woman Serious uncontrolled disease intercurrent infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>DA-EPOCH-R</keyword>
</DOC>